The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness;Gesundheitsökonomie der aufmerksamkeitsdefizit-/hyper- aktivitätsstörung in deutschland Teil 2: Therapeutische optionen und ihre kosteneffektivität

Nervenarzt

Volumn 81, Issue 3, 2010, Pages 301-314

  Schlander, M ^a,b,c   Trott, G E ^a,d   Schwarz, O ^a,e  

^a Institute for Innovation and Valuation in Health Care (InnoValHC)   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Hochschule für Wirtschaft Ludwigshafen am Rhein   (Germany)

^d Hochschule Heilbronn ^*

^e HEILBRONN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; COST EFFECTIVENESS ANALYSIS; GERMANY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; REVIEW; ARTICLE; CHILD; ECONOMICS; FEMALE; MALE; PREVALENCE; STATISTICS; UTILIZATION REVIEW;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; MALE; PREVALENCE; UTILIZATION REVIEW;

EID: 77953262685     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-009-2889-8     Document Type: Review

References (100)

1. Sozialgesetzbuch (SGB), Fünftes Buch (V): Gesetzliche Krankenversicherung. §2, Abs. 4
2. Schlander M (2007) Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription drug spending for children and adolescents: increasing relevance of health economic evidence. Child Adolesc Psychiatry Ment Health 1:13
3. Schlander M, Trott GE, Schwarz O (2009) Gesundheitsökonomie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung in Deutschland (Teil 1): Versorgungsepidemiologie und Krankheitskosten. Nervenarzt (im Druck)
4. Torrance GW, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5(4):559-575
5. Luebbe W (2001) Rationing - basic philosophical principles and the practice. In: Breyer F, Kliemt H, Thiele F (eds) Rationing in Medicine: Ethical, Legal and Practical Aspects. Springer, Berlin, S 105-117
6. Schlander M (2003) Zur Logik der Kosteneffektivität. Gesundheitsökonomie und Ressourcenallokation. Dtsch Ärztebl 100(33):A2140-A2141
7. Schlander M (2005) Kosteneffektivität und Ressourcenallokation: Gibt es einen normativen Anspruch der Gesundheitsökonomie? In: Kick HA, Taupitz J (Hrsg) Gesundheitswesen zwischen Wirtschaftlichkeit und Menschlichkeit. LIT, Münster, 37-112
8. Dolan P, Shaw R, Tsuchiya A, Williams A (2005) QALY maximisation and people's preferences: a methodological review of the literature. Health Econ 14(2):197-208
9. Richardson J, McKie J (2007) Economic evaluation of services for a National Health Scheme: the case for a fairness-based framework. J Health Econ 26(4):785-799
10. Schlander M (2009) Der Effizienz auf der Spur. Z Evidenz Fortb Qual Gesundheitsw (im Druck)
11. Drummond MF, Sculpher MJ, Torrance GW et al (2005) Methods for the economic evaluation of health care programmes. 3. edn. Oxford Univ Press, Oxford,
12. Schlander M (2007) Health Technology Assessments by the National Institute for Health and Clinical Excellence: A Qualitative Study. Springer, New York, NY
13. Loeber R, Green SM, Lahey BB, Stouthamer-Loeber M (1999) Differences and similarities between children, mothers, and teachers as informants on disruptive child behavior. J Abnorm Child Psychol 19:75-95
14. Fischer M, Barkley RA, Fletcher KE, Smallish L (1993) The stability of dimensions of behaviour in ADHD and normal children over an 8-year follow-up. J Abnorm Child Psychol 21:315-337
15. Danckaerts M, Heptinstall E, Chadwick O, Taylor E (1999) Self-report of attention deficit hyperactivity disorder in adolescents. Psychopathology 32:81-92
16. De Civita M, Regier D, Alamgir AH et al (2005) Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics 23(7):659-685
17. Griebsch I, Coast J, Brown J (2005) Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 115:e600-e614
18. Ravens-Sieberer U, Erhart M, Wille N et al (2006) Generic health-related quality-of-life assessment in children and adolescents: methodological considerations. Pharmacoeconomics 24(12):1199-1220
19. M Schlander (2007) Lost in Translation? Over-Reliance on QALYs May Lead to Neglect of Relevant Evidence. 6th World Congress of the International Health Economics Association (iHEA), Copenhagen / Denmark, July 8-11, Published online at http://www.papers.ssrn.com/sol3/papers.cfm?abstract-id=992668 (Social Science Research Net)
20. McGregor M (2003) Cost-utility analysis: use QALYs only with great caution. Can Med Assoc J (CMAJ) 168(4):433-434
21. Klassen A, Miller A, Fine S (2004) Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114(5):541-547
22. Retz-Junginger P, Sobanski E, Alm B et al (2008) Alters- und geschlechtsspezifische Besonderheiten der Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung. Nervenarzt 79:809-819
23. Jans T, Kreiker S, Warnke A (2008) Multimodale Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Kindesalter. Nervenarzt 79:791-800
24. Jacob CP, Philipsen A, Ebert D, Deckert J (2008) Multimodale Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter. Nervenarzt 79:801-808
25. Arbeitsgemeinschaft (AG), ADHS der Kinder- und Jugendärzte e.V. Leitlinie: ADHS (Aufmerksamkeits-Defizitshyperaktivitäts-Störung) bei Kindern und Jugendlichen. Forchheim: Aktualisierte Fassung Januar 2007
26. Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie (Hrsg) (2007) Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. 3. Aufl. Deutscher Ärzteverlag, Köln
27. American Academy of Child and Adolescent Psychiatry (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41 [Suppl 2]:26-49
28. American Academy of Pediatrics (2001) Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108(4):1033-1044
29. Kassenärztliche Bundesvereinigung (KBV) (2008) Qualitä tsgesicherte Versorgung von Kindern und Jugendlichen mit ADHS/ADS. Ein Konzept der Vertragswerkstatt. KBV, Berlin
30. Schachar R, Jadad AR, Gauld M et al (2002) Attention-deficit hyperactivity disorder: critical appraisal of extended treatment studies. Can J Psychiatry 47(4):337-348
31. Jadad AR, Boyle M, Cunningham C et al (1999) Treatment of Attention-Deficit/Hyperactivity Disorder. Evidence Report/Technology Assessment No 11 (prepared by McMaster University under contract no 290-97-0017). AHRQ Publication No 00-E005. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD
32. Arnold LE, Abikoff HB, Cantwell DP et al (1997) National Institute of Mental Health Collaborative Multimodal Treatment Study of children with ADHD (the MTA). Design challenges and choices. Arch Gen Psychiatry 54:865-870
33. MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086
34. MTA Cooperative Group (1999) Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1088-1096
35. MTA Cooperative Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113(4):754-761
36. Jensen PS, Arnold LE, Swanson JM et al (2007) 3-year follow-up of the NIMH MTA Study. J Am Acad Child Adolesc Psychiatry 46(8):989-1002
37. Greenhill LL, Swanson JM, Vitiello B et al (2001) Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 40(2):180-187
38. Vitiello B, Severe JB, Greenhill LL et al (2001) Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 40(2):188-196
39. Wells KC, Pelham WE, Kotkin RA et al (2000) Psychosocial treatment strategies in the MTA Study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol 28(6):483-505
40. Abikoff H, Arnold LE, Newcorn JH et al (2002) Emergency/adjunct services and attrition prevention for randomized clinical trials in children: the MTA manual-based solution. J Am Acad Child Adolesc Psychiatry 41(5):498-504
41. Hack S, Chow B (2001) Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 11(19):59-67
42. Arnold LE, Abikoff HB, Cantwell DP et al (1997) NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. J Atten Disord 2(3):141-158
43. Pelham WE (1999) The NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder: just say yes to drugs alone? Can J Psychiatry 44:981-990
44. Swanson JM, Kraemer HC, Hinshaw SP et al (2001) Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40(2):168-179
45. Arnold LE, Chuang S, Davies M et al (2004) Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. J Abnorm Child Psychol 32(1):39-51
46. Arnold LE, Molina B, Swanson J et al (2005) New ADHD Insights from MTA Data Through 36 Months. 52nd Annual Meeting of the American Academy of Child & Adolescent Psyciatry (AACAP) and 25th Canadian Academy of Child and Adolescent Psychiatry (CAPAP) Annual Meeting, Toronto, Ontario, October 18-23, Sci Proc 25D:p 25
47. Swanson JM, Hinshaw SP, Arnold LE et al (2007) Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 46(8):1003-1014
48. Molina BSG, Flory K, Hinshaw SP et al (2007) Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46(8):1028-1040
49. Barbaresi WJ, Katusic Slavica K, Colligan R et al (2007) Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr 28(4):265-273
50. Barbaresi WJ, Katusic Slavica K, Colligan R et al (2007) Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr 28(4):274-287
51. Jensen PS, Hinshaw SP, Kraemer HC et al (2001) ADHD comorbidity findings from the MTA Study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40(2):147-158
52. Jensen PS, Garcia JA, Glied S et al (2005) Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 162(9):1628-1636
53. Foster EM, Jensen PS, Schlander M et al (2007) Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Serv Res 42(1):165-182
54. Santosh PJ, Taylor E, Swanson J et al (2005) Refining the diagnoses of inattention and overactivity syndromes: a reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clin Neurosci Res 5:307-314
55. Abikoff H, Hechtman L, Klein RG et al (2004) Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43(7):820-829 (Pubitemid 38808487)
56. Hechtman L, Abikoff H, Klein RG et al (2004) Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43(7):812-819 (Pubitemid 38808486)
57. Chronis AM, Jones HA, Raggi VL (2006) Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. Clin Psychol Rev 26:486-502
58. Ebert D, Krause J, Roth-Sackenheim C (2003) ADHS im Erwachsenenalter. Letlinien auf der Basis eines Expertenkonsensus. Nervenarzt 74:939-946
59. Fritze J, Schmauss M (2002) Off-Label-Use: Der Fall Methylphenidat. Nervenarzt 73:1210-1212
60. Banaschewski T, Coghill D, Santosh P et al (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15(8):476-495
61. King S, Griffin S, Hodges Z et al (2006) A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess (Rockv) 10(23)
62. Schlander M, Schwarz O, Trott GE et al (2005) Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Are U.S. cost-effectiveness findings based upon the MTA Study relevant to mental health care policy makers in Germany? Value Health 8(6):A197
63. Schlander M, Schwarz O, Hakkaart-van Roijen L et al (2006) Cost-Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/ Hyperactivity Disorder (ADHD) in the United States, Germany, The Netherlands, Sweden, and United Kingdom. Value Health 9(6)A312
64. Towse A, Pritchard C, Devlin N (Hrsg) (2002) Cost-effectiveness thresholds. Economic and ethical issues. King's Fund and Office of Health Economics, London
65. Schlander M, Schwarz O, Hakkaart-van Roijen L et al (2006) Functional impairment of patients with attention-deficit/hyperactivity disorder (ADHD): an alternative cost-effectiveness analysis of clinically proven treatment strategies based upon the NIMH MTA Study. Value Health 9(6):A312
66. Schlander M, Schwarz O, Foster EM et al (2006) Cost-effectiveness of clinically proven treatment strategies for attention-deficit/hyperactivity disorder (ADHD): Impact of coexisting conditions. Value Health 9(6):A309
67. Bird H, Shaffer D, Fisher P, Gould M (1993) The Columbia Impairment Scale (CIS): pilot findings on a measure of global impairment for children and adolescents. Int J Methods Psychiatr Res 3:167-176
68. Annemans L, Ingham M (2000) Estimating cost-effectiveness of Concerta OROS in attention-deficit/hyperactivity disorder (ADHD) - adapting the Canadian Coordinating Office for Health Technology Assessment's (CCOHTA) economic model of methylphenidate immediate release versus behavioural interventions from a parent's perspective. Value Health 5(6):517
69. Schlander M (2004) Cost-effectiveness of methylphenidate OROS for attention-deficit/hyperactivity disorder (ADHD): an evaluation from the perspective of the UK National Health Service (NHS). Value Health 7(3):236
70. Faber A, van Aghtoven M, Kalverdijk LJ et al (2008) Long-acting methylphenidate-OROS in youths with attention-deficit/hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs 22(2):157-170
71. Schlander M (2009) Cost effectiveness of long-acting methylphenidate for treatment of attention-deficit/hyperactivity disorder in children and adolescents in Finland: an evaluation based upon a randomized clinical trial. Value Health (im Druck)
72. Schlander M, Trott GE, Migliaccio-Walle K, Caro J (2004) Kosteneffektivität verbesserter Compliance mit medikamentöser Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Kindern und Jugendlichen aus der Perspektive der Gesetzlichen Krankenversicherung. Jahrestagung des Berufsverbands der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie in Deutschland (BKJPP), Gelsenkirchen, Abstraktband, p 23
73. Schlander M (2007) Long-acting medications for the hyperkinetic disorders: a note on cost-effectiveness. Eur Child Adolesc Psychiatry16 (7):421-429
74. Claxton A, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296-1310
75. Swanson J (2003) Compliance with stimulants for attention-deficit/ hyperactivity disorder. Issues and approaches for improvement. CNS Drugs 17(2):117-131
76. Cox BM (1990) Drug tolerance and physical dependence. In: Pratt WB, Taylor P (eds) Principles of Drug Action: The Basis of Pharmacology. Churchill Livingstone, New York, NY, p 639-690
77. Swanson JM, Kinsbourne M, Roberts W, Zucker K (1978) A time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 61:21-29
78. Greenhill LL (1992) Pharmacologic treatment of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 15:1-27
79. Greenhill LL, Perel JM, Rudolf G et al (2001) Correlations between motor persistence and plasma levels of methylphenidate-treated boys with ADHD. Int J Neuropsychopharmacol 4:207-215
80. Meredith PA (1999) Achieving and assessing therapeutic coverage. In: Métry JM, Meyer UA (Hrsg) Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. John Wiley & Sons, Chichester, 41-60
81. Miller AR, Lalonde CE, McGrail KM (2004) Children's persistence with methylphenidate therapy: a population-based study. Can J Psychiatry 49(11):761-768
82. Schlander M, Schwarz O, Trott GE et al (2007) Is Methylphenidate Overprescribed in Germany? New Pharmacoepidemiological Data from Nordbaden on its Use in Children and Adolescents with ADHD. J Ment Health Policy Econ 10 [Suppl 1]:37
83. Schwartz D, Lellouch J (1967) Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 20:637-648
84. Weiss MD, Gadow K, Wadell MB (2006) Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67 [Suppl 8]:38-45
85. Revicki DA, Frank L (1999) Pharmacoeconomic evaluations in the real world: effectiveness versus efficacy studies. Pharmacoeconomics 15(5):423-434
86. Hughes DA, Bagust A, Haycox A, Walley T (2001) Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 19(12):1185-1197
87. Marcus SC, Wan GJ, Kemner JE, Olfson M (2005) Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 159:572-578
88. Sanchez RJ, Crismon ML, Barner JC et al (2005) Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 25(7):909-917
89. Kemner JE, Lage MJ (2006) Effect of methylphenidate formulation on treatment patterns and use of emergency room services. Am J Health Syst Pharm 63(4):317-322
90. Kemner JE, Lage MJ (2006) Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. Ann Gen Psychiatry 5(5):1-8
91. Olfson M, Marcus SC, Zhang HF, Wan GJ (2007) Continuity in methylphenidate treatment in adults with attention-deficit/hyperactivity disorder. J Manag Care Pharm 13(7):570-577
92. Steele M, Weiss M, Swanson J et al (2006) A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release-methylphenidate in attention-deficit-hyperactivity-disorder. Can J Clin Pharmacol 13 (1):e50-e62
93. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL (2008) Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and safety. Child Adolesc Psychiatr Ment Health 2:25
94. Cottrell S, Tilden D, Robinson P et al (2008) A modeled evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health 11(3):376-388
95. Hong J, Dilla T, Arellano J (2009) A modeled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. BMC Psychiatry 9:15
96. Faraone SV (2003) Understanding the effect size of ADHD medications: implications for clinical care. Medscape Psychiatry Mental Health 8:1-7
97. Steinhoff K, Wigal T, Swanson J (2003) Single daily dose ADHD medication effect size evaluation. Poster presentation, 50th Annual Meeting of the American Academy for Child and Adolescent Psychiatry, Miami, FL, 22-27
98. Steinhoff K (2004) Attention-deficit/hyperactivity disorder: medication treatment-dosing and duration of action. Am J Manag Care 10(4):S99-S106
99. Faraone SV, Biederman J, Spencer TJ, Aleardi M (2006) Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 8(4):4
100. Blanz B, Döpfner M, Fleischmann J et al (2005) Stellungnahme zur " Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ASHS)" - Langfassung. Bundesärztekammer, Berlin